The monoclonal antibody revolution has produced a wave of important new therapeutics, but developing effective antibodies remains elusive for many targets and indications. The discovery and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on ...
The two companies have committed to keep providing perpetual licenses for Affinity software. The two companies have committed to keep providing perpetual licenses for Affinity software. is a news ...
Our team tests, rates, and reviews more than 1,500 products each year to help you make better buying decisions and get more from technology. If you're searching for a professional-grade vector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback